...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Enthusiasm? NOT!

,,,Toinv and NBB,,all you note is agreed upon,,,great perspective in your first post Toinv,,,,,,we need talent and not a Pinoccio at the helm. Why there hasnt been a class action against RVX is beyond me. Seems they can appear for much less! However, I am stunned non of our BPs doing these trials have made a move in some form or fashion. From the outside it looks like we just cant launch a deal with anyone,,,,,around any molecule or within any known time frame. Many a CEO has been ousted for much less. Moral ones leave on their own to offer greater experience to take the helm!,,jmo,,,,all based on what we observe and of course dont!

Share
New Message
Please login to post a reply